Para-Ethoxyamphetamine

para-Ethoxyamphetamine
Clinical data
Other names4-Ethoxyamphetamine; 4-EA; 4-ETA; 4-EtO-A; PEtOA
Drug classPsychoactive drug; Stimulant; Monoamine releasing agent; Monoamine oxidase inhibitor
Legal status
Legal status
Identifiers
  • 1-(4-ethoxyphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H17NO
Molar mass179.263 g·mol−1
3D model (JSmol)
  • O(c1ccc(cc1)CC(N)C)CC
  • InChI=1S/C11H17NO/c1-3-13-11-6-4-10(5-7-11)8-9(2)12/h4-7,9H,3,8,12H2,1-2H3 checkY
  • Key:CCAMEVFYMFXHEN-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

para-Ethoxyamphetamine (PEtOA), also known as 4-ethoxyamphetamine (4-EA, 4-ETA, or 4-EtO-A), is a psychoactive drug of the phenethylamine and amphetamine families which is closely related to para-methoxyamphetamine (PMA). It has similar effects to PMA in animal studies, although with slightly weaker stimulant effects. Like PMA, it has prominent MAOI activity, and is likely to have similar dangers associated with its use.

See also

References

  1. ↑ Martin-Iverson MT, Yamada N, By AW, Lodge BA (December 1991). ""Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment". Journal of Psychiatry & Neuroscience. 16 (5): 253–61. PMC 1188362. PMID 1686728.
  2. ↑ Corrigall WA, Robertson JM, Coen KM, Lodge BA (January 1992). "The reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine". Pharmacology Biochemistry and Behavior. 41 (1): 165–9. doi:10.1016/0091-3057(92)90077-S. PMID 1539067. S2CID 30080516.
  3. ↑ Hegadoren KM, Greenshaw AJ, Baker GB, Martin-Iverson MT, Lodge B, Soin S (January 1994). "4-Ethoxyamphetamine: effects on intracranial self-stimulation and in vitro uptake and release of 3H-dopamine and 3H-serotonin in the brains of rats". Journal of Psychiatry & Neuroscience. 19 (1): 57–62. PMC 1188563. PMID 8148367.
  4. ↑ Martin-Iverson MT, Lodge BA (December 1991). "Effects of chronic treatment of rats with "designer" amphetamines on brain regional monoamines". Canadian Journal of Physiology and Pharmacology. 69 (12): 1825–32. doi:10.1139/y91-270. PMID 1802356.